Literature DB >> 2786454

Synergistic regulatory effects of interleukin 6 and interleukin 1 on the growth and differentiation of human and mouse myeloid leukemic cell lines.

K Onozaki1, Y Akiyama, A Okano, T Hirano, T Kishimoto, T Hashimoto, K Yoshizawa, T Taniyama.   

Abstract

We analyzed the effect of recombinant human interleukin 6 (IL-6), in combination with human recombinant interleukin 1 alpha (IL-1 alpha), on the growth and differentiation of several human and mouse myeloid leukemic cell lines, specifically U937, HL-60, M1, and its subclone M1-3b-N, into macrophage-like cells. IL-6 and IL-1 inhibited the growth of U937, M1, and M1-3b-N in a dose-dependent manner. Treatment of these cells with both IL-6 and IL-1 resulted in either an additive or a synergistic growth inhibition. IL-6 alone induced moderate differentiation of U937 and M1-3b-N, but the combination of IL-6 and IL-1 synergistically augmented this differentiation. In M1, only the combination of IL-1 and IL-6 resulted in differentiation. These two cytokines, whether alone or in combination, did not influence the growth and differentiation of HL-60. Therefore IL-6 in conjunction with IL-1 can induce differentiation in several human and mouse myeloid leukemic cell lines, although this effect varies with cell type. IL-6 did not stimulate the expression of IL-1 mRNA or IL-1 activity in U937 cells. IL-1 also failed to stimulate IL-6 production. Furthermore, the differentiation of U937 cells induced by IL-6 was not neutralized by antibody against either IL-1 alpha or IL-1 beta. The minimal differentiative effect of IL-1 was not affected by anti-IL-6 antibody. Therefore IL-6 and IL-1 appear to provide distinct signals for differentiation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2786454

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Interleukin-6 is antiproliferative to a mouse hybridoma cell line and promotive for its antibody productivity.

Authors:  F Makishima; S Terada; T Mikami; E Suzuki
Journal:  Cytotechnology       Date:  1992       Impact factor: 2.058

2.  Chimeric antigen receptor-T cells with cytokine neutralizing capacity.

Authors:  Adrian H J Tan; Natasha Vinanica; Dario Campana
Journal:  Blood Adv       Date:  2020-04-14

3.  Expression of interleukin-1 alpha, interleukin-1 beta and interleukin-6 in chronic B lymphocytic leukaemia (B-CLL) cells from patients at different stages of disease progression.

Authors:  M Aguilar-Santelises; R Magnusson; S B Svenson; A Loftenius; B Andersson; H Mellstedt; M Jondal
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

4.  Regulation of c-fgr messenger RNA levels in U937 cells treated with different modulating agents.

Authors:  L Faulkner; M Patel; P M Brickell; D R Katz
Journal:  Immunology       Date:  1992-05       Impact factor: 7.397

Review 5.  Host defense against infections and inflammations: role of the multifunctional IL-6/IFN-beta 2 cytokine.

Authors:  M Revel
Journal:  Experientia       Date:  1989-06-15

6.  Antitumor effects of recombinant interleukin-6 expressed in eukaryotic cells.

Authors:  A Eisenthal; H Kashtan; M Rabau; V Ramakrishna; S Chaitchik; Y Skornick
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.